Natera Inc NTRA

Natera Inc is a clinical genetic testing company based in Austin, Texas, operating across 90 countries worldwide. The firm is engaged in the development of non-invasive, cell-free DNA (cfDNA) testing technology, with a focus on women’s health, cancer, and organ health. The firm aims to use simple blood-drawing techniques rather than more complex forms of diagnostic testing to help effectively manage disease and inform treatment. Natera Inc was founded in 2004.

The firm has a strong focus on women’s health and on pre-natal health in particular. Products that have been developed by Natera include the Spectrum preimplantation genetic test, Anora miscarriage test, Horizon advance carrier screening test, and the Vistara single-gene NIPT. In the area of organ health, the firm has tests for those suffering from diseases of the kidneys, heart, and lungs. In the area of oncology, the firm has developed the Signatera Residual Disease test, the Altera Tumor Genomic profile, and the Empower Hereditary Cancer test.

Natera Inc has now seen more than three million of its cfDNA tests performed. The firm has been trading on the NASDAQ since 2015 and is listed under the ticker NTRA.

Follow the NTRA share price on eToro by adding this stock to your personalised watchlist.